EP0815427A1 - Testing vessel - Google Patents

Testing vessel

Info

Publication number
EP0815427A1
EP0815427A1 EP96904938A EP96904938A EP0815427A1 EP 0815427 A1 EP0815427 A1 EP 0815427A1 EP 96904938 A EP96904938 A EP 96904938A EP 96904938 A EP96904938 A EP 96904938A EP 0815427 A1 EP0815427 A1 EP 0815427A1
Authority
EP
European Patent Office
Prior art keywords
vessel
dissolution testing
testing
dissolution
insert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96904938A
Other languages
German (de)
French (fr)
Inventor
Stephen George Barnwell
Stephen John Burns
Simon Higginbottom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortecs Ltd
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of EP0815427A1 publication Critical patent/EP0815427A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G01N2013/006—Dissolution of tablets or the like

Definitions

  • This invention relates to a dissolution testing vessel, and in particular to a vessel for testing dissolution of pharmaceutical formulations, particularly buoyant pharmaceutical formulations.
  • formulations may be designed to release an initial "burst" of active ingredient followed by a steady-state release thereafter.
  • a reliable method of assessing dissolution in vivo and consequently analysing the rate of release of active ingredient (s) is required.
  • WO-A-9206680 is an example of an application relating to novel pharmaceutical formulations.
  • dissolution testing is carried out using a method based upon the USP XXII dissolution test for tablets and capsules. This test is designed to subject the samples to an environment similar to that found in the intestine.
  • a dissolution apparatus is used, again as specified by USP XXII.
  • This essentially consists of a dissolution vessel into which is placed a buffered medium in which the dissolution testing of the pharmaceutical formulation will oe carried out.
  • the sample is simply "dropped” into the medium and is allowed to float freely at the surface.
  • the body of the medium is agitated by means of a paddle which is rotated. Paddle height is adjusted so that the top edge of the blade is level with the surface of the liquid.
  • aliquots of the dissolution medium can be removed and replaced with fresh buffer. These aliquots can then be tested to determine the amount of active ingredien (s) released from the sample formulation. Th s method is described m detail by Burns et al , Int . J. Pharmaceuti cs (1995) (in press) .
  • the present invention provides a dissolution testing vessel comprising means which prevent a formulation undergoing dissolution testing from floating freely at the surface of the testing medium, but which do not prevent the testing medium from moving freely within the vessel.
  • the means will also prevent a formulation undergoing dissolution testing from sinking to the bottom of the testing medium.
  • the invention therefore provides a testing vessel which will prevent the mechanical interaction with the means of agitation described above.
  • the testing vessel of the invention is suitable for testing dissolution of both buoyant pharmaceutical formulations and sinking erodible dosage formulations.
  • the means provided divide the vessel into at least two portions, while at the same time allowing the testing medium to move freely between those portions.
  • the means consists of an insert, which is provided as a mesh or grille and typically will have substantially the same diameter as that of the inner wall of the vessel.
  • this can be made of stainless steel.
  • a particularly convenient way of allowing the insert to be held in place is to provide the vessel with one or more projections which project inwardly from the wall of the vessel and on which the insert can rest.
  • a continuous projection can be provided which runs for substantially the whole of the inner circumference of the vessel, eg a collar, ridge or shoulder.
  • the insert can simply be dropped into the interior of the vessel and will sit on the collar, ridge or shoulder.
  • the one or more projections, or continuous projection respectively can be formed as part of the vessel itself. This s particularly the case if the vessel is made of plastic or glass.
  • the pharmaceutical formulation under test will remain below the insert (if it s a floating dosage form) and will not be free to float at the surface. If, however, it is a sinking erodible dosage form, it can rest on the top of the insert. The medium itself is still agitated by means of a paddle or paddles and the normal aliquots can be taken at appropriate time points to determine the amount of active ingredient (s) released.
  • the mechanical interaction between the means, for example an insert, and the formulation provides a suitable means of mechanical erosion, whether the dosage form is a floating type or sinking type, and therefore mimics the effect of the gastrointestinal tract in vivo .
  • the formulation Unlike the paddle set to surface method described by Burns et al , 1995 ( supra) , there is little tendency for the formulation to stick to the means.
  • Fi ⁇ ure 1 is a sectional view of a preferred embodiment of the invention.
  • FIG. 1 can be seen a sectional view of a preferred vessel (1) of the invention.
  • the vessel (1) is moulded with a continuous indentation(2) which runs along the entire circumference of the vessel. This effectively divides the vessel into a lower portion(3) , which represents approximately one third of the vessel's volume, and an upper portion(4) .
  • the provision of the indentation means that there is also provided a shoulder or ridge (5) which runs for the whole of the internal circumference of the vessel (1) .
  • An insert (6) is simply dropped into the vessel (1) and will rest upon the shoulder or ridge (5) .
  • a pharmaceutical formulation undergoing testing will be placed in the vessel before the insert (6) is dropped in and once the testing medium has been poured into the vessel the pharmaceutical formulation will remain within the lower portion (3) of the vessel (1) and will be prevented from floating freely at the surface of the testing medium by the insert (6) .
  • a dissolution study was carried out with a floating dosage form, size '0' enteric-coated capsules containing a granule preparation of salmon calcitonin with a potency of 400 iu per capsule.
  • the dissolution medium volume 900 ml, was maintained at 37°C ⁇ 1°C and contained 5.84 g.l" 1 disodium hydrogen orthophosphate, 4.61 g.l "1 potassium dihydrogen orthophosphate, 2.00 g.l 1 sodium cnolate and 1.00 g.l ' sodium deoxycholate adjusted to pH 6.8.
  • 5 ml samples of dissolution medium were removed for analysis.
  • Samples were removed at specific intervals (eg 10, 15, 20, 25 mm) , up to 30 mm, n each case the volume being replaced with fresh dissolution medium.
  • the calcitonm content of the samples was determined by a specific ELISA for salmon calcitonm and quantified by comparison with authentic standards.
  • the paddle rotation speed in both cases was 100 rpm.
  • the values are means of 6 determinations ⁇ SD, with the coefficient of variance shown in brackets, and are expressed as percentage salmon calcitonin released from the dosage form.
  • Table 1 show that the extent and rate of calcitonin . release from a floating dosage form is considerably less than using the method described in the present invention. Another observation is the reduced variability in the measurements at each point with the present invention compared with the standard method illustrated by the lower coefficient of variance.
  • any suitably shaped vessel can be used, of any suitable material.
  • the means provided with the vessel for preventing the pharmaceutical formulation from floating freely at the surface of the testing medium can simply be adapted to the vessel shape. All such variations are intended to be within the scope of the present invention.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Devices For Use In Laboratory Experiments (AREA)

Abstract

A dissolution testing vessel comprising means which prevent a formulation undergoing dissolution testing from floating freely at the surface of the testing medium, but which do not prevent the testing medium from moving freely within the vessel. In particular, the means consists of a mesh or grille.

Description

TESTING VESSEL
This invention relates to a dissolution testing vessel, and in particular to a vessel for testing dissolution of pharmaceutical formulations, particularly buoyant pharmaceutical formulations.
In the field of pharmaceutical formulations there exists a need to study the behaviour of the formulations in vitro in such a way that the in vivo behaviour of the formulations can be predicted. Many different types of formulation are produced, for example, slow-release formulations which are designed to release active ingredient (s) over a given period of time at an approximately constant rate.
Other formulations may be designed to release an initial "burst" of active ingredient followed by a steady-state release thereafter. For these various types of formulation, a reliable method of assessing dissolution in vivo and consequently analysing the rate of release of active ingredient (s) is required.
WO-A-9206680 is an example of an application relating to novel pharmaceutical formulations. In that disclosure dissolution testing is carried out using a method based upon the USP XXII dissolution test for tablets and capsules. This test is designed to subject the samples to an environment similar to that found in the intestine.
In that test a dissolution apparatus is used, again as specified by USP XXII. This essentially consists of a dissolution vessel into which is placed a buffered medium in which the dissolution testing of the pharmaceutical formulation will oe carried out. The sample is simply "dropped" into the medium and is allowed to float freely at the surface. The body of the medium is agitated by means of a paddle which is rotated. Paddle height is adjusted so that the top edge of the blade is level with the surface of the liquid. Then, at various time points throughout the test, aliquots of the dissolution medium can be removed and replaced with fresh buffer. These aliquots can then be tested to determine the amount of active ingredien (s) released from the sample formulation. Th s method is described m detail by Burns et al , Int . J. Pharmaceuti cs (1995) (in press) .
There is, however, a problem with this adaptation of a traditional type testing method, in that since the sample can float freely at the surface of the liquid t can in fact be caught up by the paddle and indeed the formulation under test could even stick to the paddle. Clearly, this may result in a delay in the breakdown of the formulation, and hence release of active ingredient (s) , by virtue of the reduced mechanical action of the paddle on an erodible formulation.
There thus exists a need to provide a dissolution testing vessel which overcomes this problem and allows the dissolution testing to be carried out on pharmaceutical formulations without any mechanical interaction between the formulation and the means used to agitate the medium m which the testing is being carried out. There is also required a means of assessing drug release from floating dosage forms without the sampling errors encountered when the dosage form is floating close to the surface of the dissolution medium. Similarly, it would be useful to have dissolution testing apparatus which could be used to assess drug release reliably from a sinking, erodible, dosage form.
Thus, the present invention provides a dissolution testing vessel comprising means which prevent a formulation undergoing dissolution testing from floating freely at the surface of the testing medium, but which do not prevent the testing medium from moving freely within the vessel.
In a preferred embodiment, the means will also prevent a formulation undergoing dissolution testing from sinking to the bottom of the testing medium.
The invention therefore provides a testing vessel which will prevent the mechanical interaction with the means of agitation described above. In particular, the testing vessel of the invention is suitable for testing dissolution of both buoyant pharmaceutical formulations and sinking erodible dosage formulations.
Suitably, the means provided divide the vessel into at least two portions, while at the same time allowing the testing medium to move freely between those portions. In a preferred embodiment of the invention the means consists of an insert, which is provided as a mesh or grille and typically will have substantially the same diameter as that of the inner wall of the vessel. Suitably this can be made of stainless steel.
A particularly convenient way of allowing the insert to be held in place is to provide the vessel with one or more projections which project inwardly from the wall of the vessel and on which the insert can rest.
Alternatively, a continuous projection can be provided which runs for substantially the whole of the inner circumference of the vessel, eg a collar, ridge or shoulder. Thus, the insert can simply be dropped into the interior of the vessel and will sit on the collar, ridge or shoulder.
Suitably, the one or more projections, or continuous projection respectively, can be formed as part of the vessel itself. This s particularly the case if the vessel is made of plastic or glass.
Therefore, m use, the pharmaceutical formulation under test will remain below the insert (if it s a floating dosage form) and will not be free to float at the surface. If, however, it is a sinking erodible dosage form, it can rest on the top of the insert. The medium itself is still agitated by means of a paddle or paddles and the normal aliquots can be taken at appropriate time points to determine the amount of active ingredient (s) released.
The mechanical interaction between the means, for example an insert, and the formulation, provides a suitable means of mechanical erosion, whether the dosage form is a floating type or sinking type, and therefore mimics the effect of the gastrointestinal tract in vivo . Unlike the paddle set to surface method described by Burns et al , 1995 ( supra) , there is little tendency for the formulation to stick to the means.
A preferred embodiment of the invention (used to assess a floating dosage form) will now be described with reference to the accompanying drawing in which:
Fiσure 1 : is a sectional view of a preferred embodiment of the invention.
In Figure 1 can be seen a sectional view of a preferred vessel (1) of the invention. The vessel (1) is moulded with a continuous indentation(2) which runs along the entire circumference of the vessel. This effectively divides the vessel into a lower portion(3) , which represents approximately one third of the vessel's volume, and an upper portion(4) . The provision of the indentation means that there is also provided a shoulder or ridge (5) which runs for the whole of the internal circumference of the vessel (1) . An insert (6) is simply dropped into the vessel (1) and will rest upon the shoulder or ridge (5) . A pharmaceutical formulation undergoing testing will be placed in the vessel before the insert (6) is dropped in and once the testing medium has been poured into the vessel the pharmaceutical formulation will remain within the lower portion (3) of the vessel (1) and will be prevented from floating freely at the surface of the testing medium by the insert (6) .
EXAMPLE 1; Comparison of Modified and Existing
Dissolution
A dissolution study was carried out with a floating dosage form, size '0' enteric-coated capsules containing a granule preparation of salmon calcitonin with a potency of 400 iu per capsule. The dissolution medium, volume 900 ml, was maintained at 37°C ± 1°C and contained 5.84 g.l"1 disodium hydrogen orthophosphate, 4.61 g.l"1 potassium dihydrogen orthophosphate, 2.00 g.l 1 sodium cnolate and 1.00 g.l ' sodium deoxycholate adjusted to pH 6.8. To determine the release of salmon calcitonm from the floating capsules, 5 ml samples of dissolution medium were removed for analysis. Samples were removed at specific intervals (eg 10, 15, 20, 25 mm) , up to 30 mm, n each case the volume being replaced with fresh dissolution medium. The calcitonm content of the samples was determined by a specific ELISA for salmon calcitonm and quantified by comparison with authentic standards.
The two dissolution methods compared were as follows:
METHOD A - BP Type II apparatus with the paddles set to the surface of the dissolution medium as described by Burns et al (1995) , Int. J. Pharm . (in press) ;
METHOD B - the present invention.
The paddle rotation speed in both cases was 100 rpm.
Results
The results of the study comparing the two dissolution methods are shown m Table 1.
TABLE 1
Time Standard Present (min) Method Invention A B
0 0 0
10 <2 <2
15 2.5 ± 27 (>200) 22 ± 19 (95)
20 20 ± 32 (160) 54 + 21 (39)
25 50 ± 24 (48) 82 + 7 (9)
30 73 ± 2 (3) 90 ± 8 (9)
The values are means of 6 determinations ± SD, with the coefficient of variance shown in brackets, and are expressed as percentage salmon calcitonin released from the dosage form.
The results in Table 1 show that the extent and rate of calcitonin . release from a floating dosage form is considerably less than using the method described in the present invention. Another observation is the reduced variability in the measurements at each point with the present invention compared with the standard method illustrated by the lower coefficient of variance.
The skilled man will appreciate that any suitably shaped vessel can be used, of any suitable material. In addition, the means provided with the vessel for preventing the pharmaceutical formulation from floating freely at the surface of the testing medium can simply be adapted to the vessel shape. All such variations are intended to be within the scope of the present invention.

Claims

CLAIMS :
1. A dissolution testing vessel comprising means which prevent a formulation undergoing dissolution testing from floating freely at the surface of the testing medium, but which do not prevent the testing medium from moving freely within the vessel .
2. A dissolution testing vessel as claimed m claim 1 wherein the means comprises an insert.
3. A dissolution testing vessel as claimed in claim 2 wnerem the insert has substantially the same diameter as the inner wall of the vessel .
4. A dissolution testing vessel as claimed claim 2 or claim 3 wherein the insert consists of a mesh or grille.
5. A dissolution testing vessel as claimed any one of claims 2 to 4 wherein the insert s made of stainless steel .
6. A dissolution testing vessel as claimed any one of claims 1 to 5 wherein the vessel is provided with one or more projections projecting inwardly from the interior wall of the vessel .
7. A dissolution testing vessel as claimed in any one of claims 1 to 5 wherein the vessel is provided with a continuous projection, projecting inwardly from the interior wall of the vessel, which runs for substantially the whole of the inner circumference of the vessel.
8. A dissolution testing vessel as claimed in claim 6 or claim 7 wherein the one or more projections or continuous projection respectively are formed as part of the vessel itself .
9. A dissolution testing vessel as climed in any one of claims 1 to 8 which is constructed of glass or plastic.
10. A dissolution testing vessel as claimed in claim 1 which is for use with pharmaceutical formulations.
11. The use of a dissolution testing vessel as defined in any one of claims 1 to 10 in the dissolution testing of a pharmaceutical formulation.
12. A dissolution testing vessel as claimed in claim 1 substantially as hereinbefore described with reference to the accompanying drawings.
EP96904938A 1995-03-10 1996-03-04 Testing vessel Withdrawn EP0815427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9504893 1995-03-10
GBGB9504893.0A GB9504893D0 (en) 1995-03-10 1995-03-10 Testing vessel
PCT/GB1996/000493 WO1996028717A1 (en) 1995-03-10 1996-03-04 Testing vessel

Publications (1)

Publication Number Publication Date
EP0815427A1 true EP0815427A1 (en) 1998-01-07

Family

ID=10771008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96904938A Withdrawn EP0815427A1 (en) 1995-03-10 1996-03-04 Testing vessel

Country Status (12)

Country Link
EP (1) EP0815427A1 (en)
JP (1) JPH11503517A (en)
KR (1) KR19980702844A (en)
AU (1) AU4885396A (en)
BR (1) BR9607230A (en)
CA (1) CA2214998A1 (en)
FI (1) FI973639A0 (en)
GB (1) GB9504893D0 (en)
IL (1) IL117407A0 (en)
NO (1) NO974156D0 (en)
WO (1) WO1996028717A1 (en)
ZA (1) ZA961920B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19725015C2 (en) * 1997-06-13 2002-02-14 Bayer Ag Sinker for determining the rate of release of active substances
DE60316344T2 (en) * 2002-12-16 2008-06-12 N.V. Organon CONTAINER, DEVICE AND METHOD FOR TESTING THE DISSOLUTION OF PHARMACEUTICAL COMPOSITIONS
US7357046B2 (en) 2002-12-16 2008-04-15 N. V. Organon Method for dissolution testing of a pharmaceutical delivery device
TW200732644A (en) * 2005-10-25 2007-09-01 Rohm & Haas Dissolution test equipment and methods for testing having improved filtration system
DE202008014226U1 (en) 2008-10-21 2010-11-18 Levin, Felix, Dr. Test system for quick and easy analysis of substances in liquids
DE102009042345A1 (en) 2008-10-21 2010-05-12 Levin, Felix, Dr. Test system for determination of substances in e.g. urine of potentially infected patients, has test formulations provided in cup or in container and forming stable product during contact with substances in liquid in cup
CN109884281B (en) * 2019-04-12 2023-12-01 中国地质科学院岩溶地质研究所 Test device for on-line monitoring carbonate corrosion
JP7390069B1 (en) * 2022-09-20 2023-12-01 クラシエ株式会社 Drug holder, dissolution test device, and drug dissolution test method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862042A (en) * 1974-02-27 1975-01-21 Becton Dickinson Co Serum/plasma separator - piston with red-cell trapping surfaces
FR2546628B1 (en) * 1983-05-27 1987-02-13 Univ Bordeaux DEVICE FOR STUDYING THE RELEASE-DISSOLUTION OF MEDICINAL PRODUCTS FROM PASTY PHARMACEUTICAL FORMS
CA1274159A (en) * 1986-06-19 1990-09-18 Joseph K.S. Lee Dissolution cell and method for determining the in- vitro release of a drug
FR2655874B1 (en) * 1989-12-20 1992-03-13 Prolabo Sa SOLID DISSOLUTION CELL AND DISSOLUTION KINETICS STUDY APPARATUS COMPRISING SAME.
EP0712490B1 (en) * 1993-08-06 2002-05-29 Novartis AG Apparatus for simulating the effect of the living organism on the change in shape, the disintegration and dissolution behaviour and the active-ingredient release of a pharmaceutical dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9628717A1 *

Also Published As

Publication number Publication date
BR9607230A (en) 1997-11-11
KR19980702844A (en) 1998-08-05
FI973639A (en) 1997-09-09
ZA961920B (en) 1997-09-08
IL117407A0 (en) 1996-07-23
JPH11503517A (en) 1999-03-26
MX9706805A (en) 1997-11-29
AU4885396A (en) 1996-10-02
WO1996028717A1 (en) 1996-09-19
FI973639A0 (en) 1997-09-09
GB9504893D0 (en) 1995-04-26
NO974156L (en) 1997-09-09
NO974156D0 (en) 1997-09-09
CA2214998A1 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
TWI257302B (en) Controlled-release of an active substance into a high fat environment
EA002482B1 (en) Sertraline salts and sustained-release dosage forms of sertraline
Sethi et al. A QbD approach for the fabrication of immediate and prolong buoyant cinnarizine tablet using polyacrylamide-g-corn fibre gum
EP0815427A1 (en) Testing vessel
Thahera et al. Formulation and evaluation of Norfloxacin gastro retentive drug delivery systems using natural polymers
Wilde et al. Development of a pressure-sensitive glyceryl tristearate capsule filled with a drug-containing hydrogel
Soltero et al. Effects of sinker shapes on dissolution profiles
CN116600791A (en) Pharmaceutical preparation
Kondo et al. Characteristics of the gastric pH profiles of unfed and fed cynomolgus monkeys as pharmaceutical product development subjects
Hussain et al. Formulation and evaluation of gastro retentive floating tablets of simvastatin using hydrophilic rate retardant
Jadhav et al. Design and In-vitro Evaluation expandable Gastro retentive tablets of Diltiazem Hydrochloride
Nihar et al. Design and development of controlled porosity osmotic tablets of captopril
Rayate et al. Formulation and evaluation of fast dissolving tablets of pioglitazone
MXPA97006805A (en) Pru container
Sravya et al. Formulate gastroretentive floating bioadhesive drug delivery system of nizatidine by direct compression technique: https://doi. org/10.54037/WJPS. 2022.100106
EA035974B1 (en) Method for determining the disintegration time of a film-shaped pharmaceutical dosage form, disintegration testing device and use of said device
Thapa et al. FORMULATION AND IN-VITRO EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF DOMPERIDONE.
Satish et al. Design and optimization of fast dissolving tablets containing metoprolol by sublimation method
Chaibva et al. The comparison of in vitro release methods for the evaluation of oxytocin release from pluronic® F127 parenteral formulations
Khamkat et al. Formulation and Evaluation of Propranolol Hydrochloride Sustained Release Matrix Tablets Using Different Grades of HPMC and MCC.
Malvey et al. Development and Evaluation of floating pulsatile drug delivery system of meloxicam
Fotaki et al. In Vitro Product Performance Testing of Oral Drug Products: View of the USP Expert Panel
DE60316344T2 (en) CONTAINER, DEVICE AND METHOD FOR TESTING THE DISSOLUTION OF PHARMACEUTICAL COMPOSITIONS
Crombeen et al. In vitro testing of controlled release theophylline preparations: Theolair®, Theograd® and Theolin®
Kulkarni et al. Formulation and Evaluation of Paracetamol Tablets using Coconut Oil as a Binder

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980114

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORTECS (UK) LIMITED

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORTECS (UK) LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980725

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1001980

Country of ref document: HK